3D hypoxia-preconditioned UC-MSCs

Developed for: aplastic anemia · bone marrow failure syndrome
Investigated by: Beijing 302 Hospital · Beijing Friendship Hospital · Beijing GeniusCure Biotechnology Co., Ltd. · Chinese PLA General Hospital · Fourth Medical Center of PLA General Hospital · Pollon Life Co., Ltd.
+4 more
· Shenzhen University General Hospital · The First Medical Center of Chinese PLA General Hospital · The University of Hong Kong-Shenzhen Hospital · Yan'an University Affiliated Hospital

today NCT07299123 · Ph 1/2

20232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT07299123	Aug 2022 → Dec 2026 expected	aplastic anemia, bone marrow failure syndrome	Chinese PLA General Hospital	Enrolling by invitation	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	3D hypoxia-preconditioned UC-MSCs	“5 × 10⁵/kg 3D hypoxia-preconditioned UC-MSCs at 4 h before HSC infusion” NCT07299123 ↗
Modality	Cell therapy	“Hypoxic 3D-Cultured Umbilical Cord Mesenchymal Stem Cells” NCT07299123 ↗